Abstract 3236
Background
Targeted therapies have increasingly placed drug cost in the spotlight. This represents only one aspect of cancer treatment cost. To provide a comprehensive view, we analyzed first-year drug costs, procedures and acute care interventions for a NSCLC patients on chemo vs TT in the 1L setting.
Methods
Using Inovalon's MORE2 Registry® US claims data, aNSCLC pts were identified by International Classification of Diseases-9 codes from July 2013 to June 2014. Inclusion: aNSCLC pts >18 years who received 1L systemic therapy within 6 months (mo) of diagnosis. Exclusion: pts with small-cell lung cancer or secondary malignancies, clinical trial pts, pts with
Results
Of 5319 1L pts, 1070 (20%) had ≥12 mo of follow-up and were included in the analysis. Of those, 23% received TT (242 pts); 62% (659 pts) incurred inpatient costs. Results of the analysis are presented in the table.
| All pts (N = 1070) | Pts with inpatient costs (N = 659) | TT pts (N = 242) | Chemo pts (N = 828) | |
|---|---|---|---|---|
| Mean follow-up, mo | 20.3 | 21.3 | 21.2 | 20.1 |
| Mean 1L TC, $ | 110,138 | 118,898 | 150,272 | 100,624 |
| Mean 1L TC monthly, $ | 5,414 | 5,595 | 7,086 | 4,996 |
| Outpatient costs and subcategories | ||||
| Outpatient costs, % | 87 | 79 | 92 | 86 |
| Systemic therapy | 27 | 21 | 59 | 19 |
| Supportive care | 11 | 10 | 2 | 14 |
| Office visits | 2 | 2 | 2 | 2 |
| Labs & diagnostics | 2 | 2 | 2 | 2 |
| Radiation/surgery | 2 | 2 | 1 | 2 |
| Other drugsa | 26 | 26 | 18 | 28 |
| Other procedures | 17 | 16 | 9 | 19 |
| Inpatient costs, % | 13 | 21 | 8 | 14 |
aMay not have been related to a NSCLC
Conclusions
The study showed considerable TC in 1L aNSCLC, with systemic therapy representing a significant share. Pts with inpatient care incurred higher TC, and chemo pts had a higher share of inpatient costs vs TT pts. Alternatives to traditional chemo may allow for savings across non-drug-related outpatient and inpatient costs.
Clinical trial identification
Legal entity responsible for the study
Bristol-Myers Squibb
Funding
Bristol-Myers Squibb
Disclosure
J. Radtchenko: Participation in funded or unfunded research on a technology, process, or product development or are the principal investigator for a project related to research from Cardinal Health, analyst and study director. B. Korytowsky, K. Tuell: Employment and Stock or Other Ownership from BMS. All other authors have declared no conflicts of interest.